top of page
LATEST NEWS
Lexeo's One-Time Gene Therapy Cut Dangerous Heart Rhythms by 80% in PKP2 Heart Disease
Interim Phase I/II results for Lexeo's LX2020 show an 80% average drop in dangerous heart-rhythm runs at the higher dose, with heart biopsies showing the missing PKP2 protein restored. The FDA is open to a faster approval path.
4 hours ago3 min read


Every Gene Therapy Approval We've Covered: FDA Decisions 2025-2026
The FDA's list of approved gene therapies now stands at 33. Every approval and rejection Gene Tech Times has covered, and the pattern they show.
17 hours ago3 min read


CRISPR for Cholesterol and Triglycerides: Everything We've Covered
Gene editing is moving from rare disease to high cholesterol and high triglycerides. Every Gene Tech Times story on PCSK9 and ANGPTL3 editing, and the argument it starts.
17 hours ago3 min read


LEARN MORE
LEARN MORE

GENE TECH TIMES
The Future Has Arrived


Base Editor Gene Therapy for CPS1 Deficiency Treats Baby’s Rare Disorder
In a historic first, doctors used base editor gene therapy to treat a baby with CPS1 deficiency, a rare genetic liver disorder. The personalized treatment—delivered using lipid nanoparticles—led to improved ammonia levels and reduced medication needs. Unlike traditional CRISPR, base editing made precise DNA changes without cutting, offering a safer, more targeted option. This breakthrough marks a major step forward in treating rare diseases with gene-editing technology.
Jul 1, 2025


Gene Therapy Restores Enzyme Levels to Treat Hypophosphatasia - A More Permanent Treatment
Hypophosphatasia (HPP), or "soft bone disease" is a rare genetic disorder that impacts bone and tooth development, leading to weak bones and other health complications. For years, enzyme replacement therapy has been the only effective treatment for HPP. This therapy involves injecting asfotase alfa, an enzyme that replaces the missing one in patients’ bodies. However, these injections must be given three to six times a week, which can be challenging for many patients. While t
Feb 4, 2025


Two New CRISPR-Based Gene Therapies for Sickle Cell Anemia Approved by the FDA
The FDA recently approved two groundbreaking CRISPR-based gene therapies for curing Sickle Cell Disease (SCD): Casgevy - developed by Vertex Pharmaceuticals and CRISPR Therapeutics Lyfgenia - developed by Bluebird Bio By targeting the BCL11A gene, these therapies successfully correct SCD mutations and increase fetal hemoglobin (HbF) levels in patients. This is exciting news for patients and families living with this painful disease, as it presents a potential cure rather than
Mar 25, 2024
bottom of page


